Formulary guidance and transparency from P&T to point of care

MMIT Reality Check on Hemophilia A or B With Inhibitors (Jun 2019)

Posted by Matt Breese on Jun 21, 2019

Find me on:

According to our recent payer coverage analysis for hemophilia A or B with inhibitors treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for hemophilia A or B with inhibitors treatments shows that under the pharmacy benefit, about 45% of the lives under commercial formularies are covered with utilization management restrictions.

MMIT-Reality Check-Hemophilia A or B with Inhibitor_2Q2019Data snapshot as of Q2 2019

Trends: Hemophilia treatments have focused on procoagulants, but researchers now are looking into therapies that target natural anticoagulants.

To read the full Reality Check on Hemophilia A or B With Inhibitors treatments with key findings on clinical characteristics, drug market access and payer coverage, please click on the button below: 


View Reality Check

Topics: Specialty, Market Access, Payer, Branding & Marketing